{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:59:59Z","timestamp":1784091599586,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate the clinical characteristics, treatments and outcomes of patients with myasthenia gravis with antibodies to muscle-specific tyrosine kinase (MuSK-MG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed the cases of 21 patients with confirmed MuSK-MG between January 2012 and January 2020 in our centre. Detailed clinical data and long-term follow-up information were summarized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Females (17\/21, 81%) predominated among these MuSK-MG patients, and the mean age of onset in this group was 51.86\u00a0\u00b1\u00a016.16\u2009years. MuSK-MG patients were divided into three subgroups according to the symptoms of muscle weakness at onset: ocular myasthenia gravis (OMG, 47.6%), bulbar myasthenia gravis (BMG, 42.9%), and generalized myasthenia gravis (GMG, 9.5%). The mean progression time from symptom onset to other muscle group involvement in OMG patients was 4.38\u00a0\u00b1\u00a02.54\u2009months. Pyridostigmine bromide was adopted in 81.0% of patients, and 90.5% of patients received corticosteroids. Compared to usage in hospitals, the median daily dose of corticosteroids decreased significantly at the last follow-up. A total of 85.7% of patients received a long-term follow-up, with an average time of 1202.17\u00a0\u00b1\u00a0976.73\u2009days. At the end of the follow-up period, 4.8% of patients had achieved complete stable remission, 42.9% of patients had minimal manifestations, 19.0% had improved, the condition of 4.8% of patients remained unchanged, and 9.5% of patients died.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Female patients were more prevalent in this study, and MuSK-MG patients rapidly progressed to a generalized state. Although approximately 50% of MuSK-MG patients can achieve a favourable outcome with conventional immunosuppressants, complete stable remission is rare, and approximately 15% respond poorly. More effective medications should be explored in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-022-02593-6","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T08:38:34Z","timestamp":1646383114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes"],"prefix":"10.1186","volume":"22","author":[{"given":"Qi","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"2593_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","volume":"48-49","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun. 2014;48-49:143\u20138.","journal-title":"J Autoimmun"},{"issue":"5","key":"2593_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475\u201390.","journal-title":"Lancet Neurol"},{"issue":"3","key":"2593_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"2593_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","volume":"44","author":"JT Guptill","year":"2011","unstructured":"Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36\u201340.","journal-title":"Muscle Nerve"},{"key":"2593_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1196\/annals.1405.012","volume":"1132","author":"A Evoli","year":"2008","unstructured":"Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci. 2008;1132:76\u201383.","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"2593_CR6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1468-1331.2007.01870.x","volume":"14","author":"K Ohta","year":"2007","unstructured":"Ohta K, Shigemoto K, Fujinami A, Maruyama N, Konishi T, Ohta M. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol. 2007;14(9):1029\u201334.","journal-title":"Eur J Neurol"},{"issue":"1","key":"2593_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16\u201323.","journal-title":"Neurology"},{"key":"2593_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.clineuro.2018.06.041","volume":"172","author":"M Li","year":"2018","unstructured":"Li M, Ren L, Zhang Y, Lv J, Fang H, Zhang J, et al. Clinical characteristics of AChRAb and MuSKAb double seropositive myasthenia gravis patients. Clin Neurol Neurosurg. 2018;172:69\u201373.","journal-title":"Clin Neurol Neurosurg"},{"issue":"3","key":"2593_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jocn.2005.04.028","volume":"13","author":"JY Lee","year":"2006","unstructured":"Lee JY, Sung JJ, Cho JY, Oh DH, Kim HJ, Park JH, et al. MuSK antibody-positive, seronegative myasthenia gravis in Korea. J Clin Neurosci. 2006;13(3):353\u20135.","journal-title":"J Clin Neurosci"},{"key":"2593_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.516211","volume":"11","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Guan Y, Han J, Li M, Shi M, Deng H. Regional features of MuSK antibody-positive myasthenia gravis in Northeast China. Front Neurol. 2020;11:516211.","journal-title":"Front Neurol"},{"issue":"3","key":"2593_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1568-9972(03)00006-5","volume":"2","author":"GS Cooper","year":"2003","unstructured":"Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2(3):119\u201325.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"2593_CR12","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.autrev.2013.03.005","volume":"12","author":"S Mori","year":"2013","unstructured":"Mori S, Shigemoto K. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis. Autoimmun Rev. 2013;12(9):912\u20137.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2593_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11910-013-0421-9","volume":"14","author":"SH Wong","year":"2014","unstructured":"Wong SH, Huda S, Vincent A, Plant GT. Ocular myasthenia gravis: controversies and updates. Curr Neurol Neurosci Rep. 2014;14(1):421.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"2593_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3988\/jcn.2009.5.2.53","volume":"5","author":"SJ Oh","year":"2009","unstructured":"Oh SJ. Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status. J Clin Neurol. 2009;5(2):53\u201364.","journal-title":"J Clin Neurol"},{"issue":"2","key":"2593_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ncl.2018.01.004","volume":"36","author":"MH Rivner","year":"2018","unstructured":"Rivner MH, Pasnoor M, Dimachkie MM, Barohn RJ, Mei L. Muscle-specific tyrosine kinase and myasthenia gravis owing to other antibodies. Neurol Clin. 2018;36(2):293\u2013310.","journal-title":"Neurol Clin"},{"issue":"1","key":"2593_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13518","volume":"1412","author":"A Evoli","year":"2018","unstructured":"Evoli A, Alboini PE, Damato V, Iorio R, Provenzano C, Bartoccioni E, et al. Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci. 2018;1412(1):82\u20139.","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"2593_CR17","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.autrev.2013.03.004","volume":"12","author":"A Evoli","year":"2013","unstructured":"Evoli A, Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev. 2013;12(9):931\u20135.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"2593_CR18","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1136\/jnnp.2004.052415","volume":"76","author":"D Lavrnic","year":"2005","unstructured":"Lavrnic D, Losen M, Vujic A, De Baets M, Hajdukovic LJ, Stojanovic V, et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry. 2005;76(8):1099\u2013102.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"2593_CR19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","volume":"89","author":"MK Hehir","year":"2017","unstructured":"Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Howard JF Jr, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology. 2017;89(10):1069\u201377.","journal-title":"Neurology"},{"issue":"4","key":"2593_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/mus.26404","volume":"59","author":"KM Clifford","year":"2019","unstructured":"Clifford KM, Hobson-Webb LD, Benatar M, Burns TM, Barnett C, Silvestri NJ, et al. Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle Nerve. 2019;59(4):404\u201310.","journal-title":"Muscle Nerve"},{"issue":"12","key":"2593_CR21","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","volume":"60","author":"DB Sanders","year":"2003","unstructured":"Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60(12):1978\u201380.","journal-title":"Neurology"},{"issue":"Pt 10","key":"2593_CR22","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1093\/brain\/awg223","volume":"126","author":"A Evoli","year":"2003","unstructured":"Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126(Pt 10):2304\u201311.","journal-title":"Brain"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02593-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02593-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02593-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T08:44:28Z","timestamp":1646383468000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02593-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2593"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02593-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-853800\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"assertion":[{"value":"28 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of the First Affiliated Hospital of Zhengzhou University. All methods in this study were performed in accordance with the relevant guidelines and regulations of our ethical files (2020-KY-231). All participants were recruited at the First Affiliated Hospital of Zhengzhou University. Written informed consent was waived by the ethics committee of the First Affiliated Hospital of Zhengzhou University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}